ArticleJournal of the National Cancer Institute2023

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.

Susan N Chi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.